Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc (LH) delivers essential clinical diagnostics and advanced laboratory solutions that shape modern medical decision-making. This dedicated news hub provides investors and healthcare professionals with timely updates on Labcorp's operational developments, scientific advancements, and strategic initiatives.
Access curated press releases and analysis covering earnings reports, partnership announcements, and innovations in precision oncology diagnostics. Track Labcorp's progress in genomic sequencing technologies and biopharma collaborations through verified updates from primary sources.
The resource consolidates critical information about Labcorp's laboratory network expansions, regulatory milestones, and service enhancements across clinical testing and drug development sectors. Users gain insights into how the company maintains its leadership through scientific rigor and operational scale.
Bookmark this page for streamlined access to Labcorp's evolving role in healthcare innovation, with updates organized for efficient navigation. Return regularly to stay informed about developments impacting diagnostic capabilities and research partnerships in the life sciences sector.
Big Health announces Gabriela Perez as its new Chief Commercial Officer to lead global commercial growth and strategy. With over 20 years of experience in healthcare technology, Perez previously managed significant growth at Ovia Health, which was acquired by Labcorp (NYSE: LH) in August 2021. She also contributed to Best Doctors, acquired by Teladoc Health (NYSE: TDOC) in June 2017. Under her leadership, Big Health aims to enhance coverage and reimbursement for digital therapeutics, leveraging its innovative products proven effective in mental health treatment.
Labcorp has launched the Enhanced Liver Fibrosis (ELF™) test, aiming to assess the risk of disease progression in patients with advanced chronic liver disease. This blood test, developed by Siemens Healthineers, has received De Novo marketing authorization from the FDA. It provides a numeric score for patients suffering from nonalcoholic steatohepatitis (NASH), enabling better treatment decisions. Approximately 20 million Americans are affected by NASH, highlighting an urgent need for improved diagnostics in this silent epidemic.
Labcorp's OmniSeq has integrated GenomOncology's Pathology Workbench to enhance its OmniSeq INSIGHT test, a genomic and immune profiling tool for solid tumors. This system analyzes 523 genes, providing insights into mutations, copy number alterations, and immune gene expression. The partnership aims to streamline variant interpretation and improve turnaround times for precision medicine. After Labcorp's acquisition of OmniSeq in June 2021, the INSIGHT test is available to U.S. clinicians and global biopharmaceuticals through Labcorp Drug Development.
Labcorp (NYSE: LH) will announce its Q4 2021 and full-year results on February 10, 2022, before the market opens. A conference call is scheduled for 9 a.m. ET on the same day, allowing stakeholders to discuss the financial outcomes. The earnings report and detailed information will be available on the Labcorp Investor Relations website. Additionally, an audio replay of the call will be accessible until February 24, 2022. Labcorp reported $14 billion in revenue for FY2020, with over 70,000 employees serving clients globally.
Labcorp (NYSE: LH) announced that its executive management team will participate in a virtual fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, at 4:30 p.m. ET. A live webcast will be available on the company's website, providing insights into its operations and strategies. Labcorp is a global life sciences leader, generating $14 billion in revenue in FY2020 and employing over 70,000 staff across more than 100 countries, focusing on diagnostics and drug development.
Labcorp (NYSE: LH) announced a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, for $450 million in cash and up to $125 million based on future performance milestones. This acquisition will enhance Labcorp's oncology portfolio and improve access to precision diagnostics globally, supporting better patient outcomes in cancer care. PGDx's innovative liquid biopsy capabilities align with Labcorp's strategic priorities, with projected revenues from PGDx expected to almost double from $22 million in 2021 to $40 million in 2022.
Labcorp (NYSE: LH) has announced a new capital allocation plan, which includes initiatives to enhance shareholder returns. The Board of Directors approved the initiation of a quarterly cash dividend, targeting a payout ratio of 15-20% of adjusted earnings, and authorized a
Labcorp (NYSE: LH) has successfully closed its acquisition of Toxikon Corporation, enhancing its nonclinical development portfolio. This strategic move aims to strengthen Labcorp's presence in the pharmaceutical and biotechnology sectors, especially in Boston, Massachusetts. The acquisition was first announced on November 18, although specific financial details remain undisclosed. Labcorp continues to grow its capabilities in providing essential insights for healthcare advancements, backed by a revenue of $14 billion in FY 2020.
Labcorp (NYSE: LH) and ConcertAI, a leader in AI and real-world data solutions, have announced a collaboration aimed at optimizing precision oncology research. This partnership seeks to improve clinical trial design, enhance patient recruitment, and ensure equitable access to trials. By leveraging ConcertAI’s software and Labcorp’s expertise, they aim to utilize real-world data and AI for more effective oncology trials. The collaboration focuses on diversity in patient recruitment and aims to generate actionable insights for quicker trial execution.
FAQ
What is the current stock price of Labcorp Holdings (LH)?
What is the market cap of Labcorp Holdings (LH)?
